



Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review

Jayne L. Chamberlain¹ · Saif Huda² · Daniel H. Whittam · Marcelo Matiello³ · B. Paul Morgan⁴ · Anu Jacob^{2,5}

Published online: 15 November 2021

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2021

Correction to: Journal of Neurology (2021) 268:1643–1664
<https://doi.org/10.1007/s00415-019-09498-4>

The original version of this article unfortunately contained a mistake. Affiliation details for Jayne L. Chamberlain were incorrectly given as “Ipsen Biopharm Ltd, 9 Ash Rd N, Wrexham LL13 9UF, UK” but should have been Ruthin, UK, e-mail: drjlc1000@gmail.com

The original article can be found online at <https://doi.org/10.1007/s00415-019-09498-4>.

✉ Jayne L. Chamberlain
drjlc1000@gmail.com

¹ Ruthin, UK

² Department of Neurology, The Walton Centre, Lower Lane, Liverpool L9 7LJ, UK

³ Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

⁴ School of Medicine, Henry Wellcome Building for Biomedical Research, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK

⁵ University of Liverpool, Liverpool, UK